Marker Therapeutics Inc

Marker Therapeutics operates with a strong liquidity position, as evidenced by a current ratio of 6.12 and cash and equivalents of $11.32 million. The company has no long-term debt, and its debt-to-equity ratio is 0.0, indicating a conservative capital structure. The price-to-book ratio of 2.07 suggests that the market values the company at a premium to its book value, although this is not uncommon for biotechnology firms with high R&D investment. The company is currently unprofitable, with a net loss of $2.39 million and an operating loss of $2.55 million in the latest period. Return on equity is negative at -20.3%, and return on assets is also negative at -16.98%, indicating that the company is not generating returns on its equity or asset base. These metrics are below the typical performance of the biotechnology industry, which often experiences early-stage losses before commercialization. Marker Therapeutics does not disclose segment or geographic revenue breakdowns in the available data, so it is not possible to assess revenue concentration or geographic exposure. The company's revenue for the latest period was $1.24 million, which is relatively low, suggesting that it is in the early stages of commercialization or clinical development. The company's growth trajectory is not clearly defined in the available data, as there is no prior revenue history provided for comparison. However, the company's current market cap of $24.34 million and the analyst price targets ranging from $5.60 to $10.00 suggest that there is some optimism about its future potential. The mean price target of $7.87 implies a potential upside of over 400% from the current market price of $1.46. The risk assessment indicates that there are no immediate liquidity or dilution flags, and the company's dilution risk is rated as low. The company has not issued additional shares recently, and there is no indication of a pending equity offering or other dilutive event. The absence of long-term debt and the high cash balance further reduce financial risk. There are no recent filings or transcripts provided in the available data to indicate any material events or developments at Marker Therapeutics. The company's financial performance and strategic direction would need to be evaluated in the context of its clinical pipeline and regulatory progress, which are not detailed in the current dataset.